LENS trial a first of its kind large scale trial shows striking 27% reduction in diabetic retinopathy progression
Presented at the ADA Diabetes Congress 2024, the LENS TRIAL was specifically designed to investigate the effect of Fenofibrate on eye outcomes in people with early diabetic retinopathy.
Over the period of four years, this trial, involving 1,151 participants, has yielded promising results in the favor of Fenofibrate:
● 27% lower risk of progression of diabetic retinopathy
● 50% reduction in the development of macular edema
● 42% reduction in the need for treatment intervention
The benefits of fenofibrate were similar in people with both T1DM and T2DM and in people with both normal and impaired kidney function
Dr. David Preiss, Associate Professor at Oxford University & Principal investigator of LENS trial, shared his expert opinion, highlighting Fenofibrate as a valuable addition to treat people with diabetic retinopathy.
Reference:
1) ADA 2024, Scientific Sessions: The Effect of Fenofibrate on Progression of Diabetic Retinopathy—Results from the LENS Trial Presented on Friday, June 21, 2024, at 3:45 PM EDT.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.